• It is to evaluate the safety and effectiveness of a lasertinib(LECLAZA) single drug in a actual medical environment for patients

  1. Primary Purpose: Progression-free survival (PFS)

  2. Secondary Purpose:

     • Objective response rate
     • Time to treatment failure
     • Adverse event (AE), serious adverse event (SAE), and adverse event of special interest (AESI)
     • Severity of (S)AE
     • duration of response (DoR)
     • Overall survival (OS)
     • Intravenous Progressive Survival Period (Intracranial PFS)
     • Relative dose intensity

• Research Design : a Multi-Center Prospective and Restrospective Cohort Study

□ the purpose of the study The study aims to explore the safety, efficacy and resistance of test drugs in patients with local progressive or metastatic epithelial growth factor T790M mutant non-small cell lung cancer who have been treated with epithelial growth factor receptor tyrosine kinase inhibitors.

This study is conducted in Korea. About 600 patients will be monitored until the first occurrence of disease progression, withdrawal of consent, failure of follow-up investigation, and death.

□ Research Procedures and Information Gathering Items There are no additional procedures performed by participating in this study and information on safety and effectiveness during the administration of Rexhraza will be followed up in routine care situations.

The information you will receive when you participate in this study is as follows.

• Subject characteristics, including age, gender, and race
• T790M Positive Mutation Status Results and Types of Tests Performed and Receptors
• a related medical history
• a physical examination
• disease characteristics
• history of chemotherapy
• associated concomitant medications
• administration of a test drug
• Safety and effectiveness
• Resistance mechanism in plasma circulation tumor DNA

Inclusion Criteria:

1. Prospective cohort

   • adults over the age of 19
   • Easter Cooperative Oncology Group performance 0-4
   • Patients who are eligible for or are being treated for test medication as per permit: patients with NSCLC with local progressive or metastatic EGFR T790M mutation who have previously been treated with Generation 1 or Generation 2 EGFR TKI
   • EGFR T790M mutation allows for all results identified in tumor tissue or plasma
   • Patients with brain MR within 3 months of study participation

2. Rectrospective cohort

   • adults over the age of 19
   • Patients who are already using the test drug according to the domestic authorization of the test drug

Exclusion Criteria:

• Patients who have a history of hypersensitivity to test drugs or drugs of similar chemical structure or similar family to those of test drugs
• Pregnant women or lactating women
• Patients participating in other interventional clinical studies

Retrospective cohort: 300 people Prospective cohort: 600 people